Page 86 - 中国全科医学2022-30
P. 86
http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·3795·
2016:33-34. south Indian HIV-infected patients[J]. J Int Assoc Physicians
[10]HAN W M,UBOLYAM S,APORNPONG T,et al. Characteristics AIDS Care (Chic),2011,10(2):71-75. DOI:
of suboptimal immune response after initiating antiretroviral therapy 10.1177/1545109710382780.
among people living with HIV with a pre-treatment CD 4 T cell count [19]杜云玲,万钢,吴焱,等 . HIV/AIDS 病人 HAART 后免疫重建
3
200 cells/mm in Thailand[J]. J Virus Erad,2020,6(3): 相关影响因素分析[J]. 中国艾滋病性病,2015,21(6):
100005. DOI:10.1016/j.jve.2020.100005. 470-473,500. DOI:10.13419/j.cnki.aids.2015.06.07.
[11]WU Z H,YANG C L,MA Y Q,et al. The prevalence of HIV- DU Y L,WAN G,WU Y,et al. Factors affecting immune
+
infected patients with virological suppression but a CD 4 T-cell reconstitution among HIV/AIDS patients[J]. Chinese Journal of
3
count of ≤ 200 cells/mm after highly active antiretroviral therapy AIDS & STD,2015,21(6):470-473,500. DOI:10.13419/j.
initiation:a meta-analysis[J]. AIDS Rev,2022,24(1): cnki.aids.2015.06.07.
16-23. DOI:10.24875/AIDSRev.21000011. [20]辛学娟,杨翠先,劳云飞,等 . HIV/AIDS 患者免疫重建的影响
[12]UNAIDS. Global HIV statistics fact sheet 2020[R/OL]. (2022-
因素与促进免疫重建的治疗策略[J]. 传染病信息,2021,34
01-16)[2022-05-14]. https://www.unaids.org/sites/default/files/
(3):265-269. DOI:10.3969/j.issn.1007-8134.2021.03.016.
media_asset/UNAIDS_FactSheet_en.pdf
XIN X J,YANG C X,LAO Y F,et al. Influencing factors
[13]田云飞,肖江,韩宁,等 . HIV/AIDS 患者高效抗逆转录病
of immune reconstitution in HIV/AIDS patients and treatment
毒治疗后免疫重建不良的特征及相关因素分析[J]. 国际
strategies to promote immune reconstitution[J]. Infectious
病 毒 学 杂 志,2014,21(4):145-150. DOI:10.3760/cma.
Disease Information,2021,34(3):265-269. DOI:10.3969/j.
j.issn.1673-4092.2014.04.001.
issn.1007-8134.2021.03.016.
[14]陈昭云,吴孔菊,孙燕,等 . 郑州市人类免疫缺陷病毒感
[21]魏秀青,陈曦,贺健梅,等 . 湖南省 AIDS 病人 HAART 过程中
染者和艾滋病患者二线抗病毒治疗效果分析[J]. 中华传
影响免疫功能重建的因素分析[J]. 中国艾滋病性病,2015,
染 病 杂 志,2017,35(5):282-285. DOI:10.3760/cma.
21(11):922-925. DOI:10.13419/j.cnki.aids.2015.11.04.
j.issn.1000-6680.2017.05.006.
WEI X Q,CHEN X,HE J M,et al. Analysis on influential factors
CHEN Z Y,WU K J,SUN Y,et al. Effect of second-line
of immune restoration in HAART in Hunan Province[J]. Chinese
antiretroviral treatment on human immunodeficiency virus/acquired
Journal of AIDS & STD,2015,21(11):922-925. DOI:
immune deficiency syndrome in Zhengzhou[J]. Chinese Journal
10.13419/j.cnki.aids.2015.11.04.
of Infectious Diseases,2017,35(5):282-285. DOI:
[22]蒋春云,诸葛银,刘秀芳,等 . 临沂市 HIV 感染者和 AIDS
10.3760/cma.j.issn.1000-6680.2017.05.006.
患者抗病毒治疗效果及影响因素分析[J]. 中国预防医学
[15]NAKANJAKO D,KIRAGGA A,IBRAHIM F,et al. Sub-optimal
杂 志,2021,22(11):868-873. DOI:10.16506/j.1009-
CD 4 reconstitution despite viral suppression in an urban cohort on
6639.2021.11.010.
antiretroviral therapy (ART) in sub-Saharan Africa:frequency
JIANG C Y,ZHUGE Y,LIU X F,et al. Effects of antiretroviral
and clinical significance[J]. AIDS Res Ther,2008,5:23.
therapy in HIV/AIDS patients and related influencing factors in Linyi
DOI:10.1186/1742-6405-5-23.
City[J]. Chinese Preventive Medicine,2021,22(11):868-
[16]YANG X D,SU B,ZHANG X,et al. Incomplete immune
873. DOI:10.16506/j.1009-6639.2021.11.010.
reconstitution in HIV/AIDS patients on antiretroviral therapy:
[23]梅馨尹,王佳洁,劳晓洁,等 . 广西艾滋病患者免疫重建不良
challenges of immunological non-responders[J]. J Leukoc Biol,
2020,107(4):597-612. DOI:10.1002/JLB.4MR1019-189R. 的预测模型建立[J]. 中国艾滋病性病,2021,27(12):
[17]凌雪梅,欧松 . 3TC+TDF+LPV/r 方案治疗免疫重建不良 AIDS 1348-1352. DOI:10.13419/j.cnki.aids.2021.12.05.
病人的临床观察[J]. 中国艾滋病性病,2014,20(3): MEI X Y,WANG J J,LAO X J,et al. Analysis on risk factors for
154-156. DOI:10.13419/j.cnki.aids.2014.03.023. immune reconstitution failure of AIDS and establishmen of prognostic
LING X M,OU S. The effect of 3TC+TDF+LPV/RTV on AIDS prediction model in Guangxi Province[J]. Chinese Journal of
patients with poor immune reconstitution[J]. Chinese Journal of AIDS & STD,2021,27(12):1348-1352. DOI:10.13419/j.
AIDS & STD,2014,20(3):154-156. DOI:10.13419/j.cnki. cnki.aids.2021.12.05.
aids.2014.03.023. [24]岑科 . 益气培元法对 HAART 后 HIV/AIDS 免疫重建不良患者 T
[18]KUMARASAMY N,VENKATESH K K,DEVALEENAL B, 淋巴细胞亚群的影响[D]. 广州:广州中医药大学,2017.
et al. Safety,tolerability,and efficacy of second-line generic (收稿日期:2022-06-06;修回日期:2022-06-17)
protease inhibitor containing HAART after first-line failure among (本文编辑:徐真)